myTomorrows   Report issue

Academic/Hospital
Founded: Amsterdam Netherlands (2012)

Organization Overview

First Clinical Trial
2017
NCT03172455
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Impatients N.V. trading as myTomorrows

Active Ingredients

Drugs in Other Trials (3)

alpha-1 antitrypsin (Prolastin) (1 trial)

imm-101 (1 trial)

uromune (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 3
  • # of Trial APIs: 3